Advantages over heparin

The new MSPs (Figs. 12.1 and 12.2) offer some advantages over heparin. They show considerably low contamination levels of virus and/or prions because they are exclusively extracted from marine sources. Contamination in clinical solutions of heparin can occur more easily, as this compound is extracted from mammalian sources, like porcine and bovine intestinal mucosa and bovine lung (Mourao, 2004). Moreover, the invertebrate MSPs are promising to be more useful clinical reagents than algal... 

Increased clotting may occur in the presence of thrombosis (enhanced formation of fibrin), stasis, and phlebitis (diminished circulation), or embolism (dislocation and lodging of blood clots). Although heparin is an extremely effective anticoagulant, it has certain limitations that are not shared by the newer thrombin inhibitors. As a result, these novel inhibitors may have advantages over heparin for use in certain clinical settings. 

In summary, bivalirudin use during PPI is safe and may prove to have an advantage over heparin. However, we caution the use of bivalirudin during PPI procedures attempting to cross and treat chronic total occlusions where the risk of perforation is substantial with an indication for immediate reversal of anticoagulation. There is no known antidote to bivalirudin. 

I like properties, have potential advantages over heparin itself. i... 

Low-molecular-weight heparin derivatives (e.g, enoxaparin) and danaparoid, a heparan with heparin-like properties, have potential advantages over heparin itself. 

A detailed examination of the affinity of SLPI for the heparinized capillary was next made using a stepwise elution (from 0.1 to 0.9 M NaCl) (Fig. 11). SLPI eluted from the capillary with 0.2 M NaCl. This agreed well with results obtained by traditional affinity chromatography on a heparin-Sepharose matrix. The ACE method has the unique advantages over traditional affinity chromatography in that it requires much smaller quantities of protein and afforded better separation profiles. 

F. Role in therapy The potential advantages of Angiomax—a direct thrombin inhibitor—over heparin include activity against clot-bound thrombin, more predictable anticoagulation, and no inhibition by components of the platelet release reaction. The place in therapy of Angiomax will be determined by further comparisons with heparin, low-molecular weight heparins, and recombinant hirudin. 

The direct thrombin inhibitors have theoretical advantages over the indirect anticoagulants that include more predictable dose-responses, and efficacy against clot bound thrombin. With bivalirudin, clinical trials suggest superiority compared with heparin alone and comparable outcomes when... 

A DTI offers several advantages over conventional heparin. They act independent of AT and are capable of inactivating free and clot-bound thrombin equally well. As a group, these agents inhibit thrombus growth and thrombin-mediated platelet activation. Several direct thrombin inhibitors have now been studied in clinical trials. 

The great advantage of warfarin over heparin is that it can be given orally. Its chief disadvantage is the time lag before it exerts its effect, which is due to its indirect mode of action. A similar time lag is found when the warfarin dose is altered or discontinued as the t/ of the nonfunctioning proteins is approximately that of functioning proteins. 

Danaparoid is as effective as heparins in inhibiting the formation of thrombi. Its major advantage over low molecular weight heparins is its low rate of cross-reactivity with heparin-associated antibodies from patients with heparin-induced thrombocytopenia (1). It is therefore indicated in patients with heparin-associated thrombocytopenia who require further anticoagulation after withdrawal of heparin. However, it should not be used if there is in vitro cross-reactivity between heparin and danaparoid. Cross-reactivity is uncommon but can result in thrombotic comphcations, as reported in a case with a fatal outcome (2). 

State at least two potential advantages of the low-molecular-weight heparins and fondaparinux over unfractionated heparin. 

The recommendation for UFH is based on documented efficacy in many older mid-sized trials. Meta-analyses showed a clear reduction in Ml and death, but at the cost of an increase in major bleeding rates (35,36). The advantages of LMWH over unfractionated heparin include a better bioavailability, a stronger and longer anti-Xa activity, less platelet activation, and no need for monitoring. A major drawback of standard heparin therapy is the potential risk of heparin-induced thrombocytopenia, which is considerably reduced with LMWH (37). 

---